Chart of the Day: Despite Volatility, Marvell Remains Attractive
The stock has been weathering the storm of the semiconductor group well.
Deeper Into the Weed
Adding meaningfully to cannabis holdings.
Long MSOS M and individual weed companies
Adding to Index Shorts
Adding to index shorts with S&P cash +30 handles:
* SPY ($SPY) $736.91
* QQQ ($QQQ) $707.94
Positions: Short SPY VS QQQ VS
Consumer-Led Slowdown
Evidence of a consumer-led slowdown appearing today in the share prices of Lowes ($LOWE) (-$9), Home Depot ($HD) (-$5), Walmart ($WMT) (-$2) and Costco ($COST) (-$11).
Positions: None.
Programming Note: Expect to Be MIA on NVDA
I have to travel this afternoon for a business dinner.
I will be leaving at around 2 p.m. and I won’t be around for the Nvidia ($NVDA) fireworks.
Positions: None.
Treasury Yield Signals Major Shift in Market Focus
Markets have moved on from President Trump and Iran and are now clearly focused on inflation.
Upside, Downside Movers in the A.M.
Upside:
-IMVT +23% (earnings, color)
-POET +15% (Marex Securities Products builds 6% stake in POET)
-TATT +14% (earnings, color)
-EGHT +12% (earnings, guidance)
-RRGB +10% (earnings, guidance)
-IBRX +8.3% (US FDA Accepts sBLA for ANKTIVA Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease)
-CAVA +7.7% (earnings, guidance)
-AMC +5.1% (CEO Adam Aron bought 250K shares at $1.377/shr)
-MRVL +4.9% (multiple broker price target raises)
-STM +4.5% (Euro semi name strength)
-LPG +3.9% (earnings, color)
-MU +3.9% (momentum amid potential memory chip shortage)
-TJX +3.8% (earnings, guidance)
-VFC +3.4% (earnings, guidance)
-PSNL +3.3% (Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company’s NeXT Personal minimal residual disease (MRD) test)
-TOL +3.3% (earnings, guidance)
-ASML +2.9% (Euro semi name strength)
-SNDK +2.4% (memory stock strength with rising memory price concerns)
-DMAC +2.3% (announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial)
Downside:
-VIAV -8.7% (prices 11.1M shares at $45.00/shr)
-NWL -2.6% (Morgan Stanley Cuts NWL to Underweight from Equal Weight, price target: $3.50)
-HAS -2.2% (earnings, guidance)
-LOW -2.1% (earnings, guidance)
Positions: None.
ETF Action in the A.M.

Positions: None.
Hyperscaler Debt Spreads
Position: None.

